KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) EBITDA: 2009-2025

Historic EBITDA for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to $35.8 million.

  • Acadia Pharmaceuticals' EBITDA rose 12.99% to $35.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $240.9 million, marking a year-over-year increase of 114.66%. This contributed to the annual value of $230.8 million for FY2024, which is 414.52% up from last year.
  • As of Q3 2025, Acadia Pharmaceuticals' EBITDA stood at $35.8 million, which was up 10.45% from $32.4 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' 5-year EBITDA high stood at $153.5 million for Q4 2024, and its period low was -$113.0 million during Q1 2022.
  • Moreover, its 3-year median value for EBITDA was $30.4 million (2024), whereas its average is $22.3 million.
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 101.73% in 2022, then surged by 902.21% in 2024.
  • Acadia Pharmaceuticals' EBITDA (Quarterly) stood at -$44.7 million in 2021, then dropped by 3.15% to -$46.1 million in 2022, then skyrocketed by 175.86% to $34.9 million in 2023, then soared by 339.28% to $153.5 million in 2024, then grew by 12.99% to $35.8 million in 2025.
  • Its last three reported values are $35.8 million in Q3 2025, $32.4 million for Q2 2025, and $19.3 million during Q1 2025.